{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:40:17Z","timestamp":1789825217147,"version":"4.0.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873335"],"award-info":[{"award-number":["81873335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"General Project of Sichuan Science and Technology Department","award":["2020YJ0376"],"award-info":[{"award-number":["2020YJ0376"]}]},{"name":"Chengdu University of Traditional Chinese Medicine science and Technology Development Fund Hospital special key project","award":["2017-EL-13"],"award-info":[{"award-number":["2017-EL-13"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Polycystic ovary syndrome (PCOS), is a common endocrine disorder in women characterized by increased androgen levels, ovulatory dysfunction, and polycystic ovaries. Western medicine is widely used for the treatment of PCOS, but patient satisfaction is low, largely due to its associated gastrointestinal symptoms of nausea and diarrhea. Guizhi Fuling Wan (GFW) is a traditional Chinese medicine used to remove blood stasis and dissipate phlegm for treating gynecological diseases that was invented by Zhang Zhongjing in the Eastern Han dynasty. In recent years, GFW has been widely used to treat patients with PCOS. This study aims to assess the efficacy and safety of GFW in the treatment of PCOS through a systematic review and meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>All randomized controlled trials connected with GFW targeting PCOS will be searched in the following electronic bibliographic databases from their earliest recorded publications to December 2020 without any language restrictions: MEDLINE, Embase, PubMed, Web of Science, China National Knowledge Infrastructure, Chinese Biological Medicine Database, Wan-fang data, Chinese Technical Periodicals, and other databases. The primary outcomes include Sex hormone levels, ovulation rate, pregnancy rate, and total effective rate. The secondary outcomes were Total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, fasting glucose, fasting insulin, insulin sensitivity index, body mass index, hypertrichosis score, acne score, adverse reactions, etc. Two reviewers will independently conduct cations retrieval, de-duplication, filtering, quality assessment, and data analysis by Endnote X9.1 and Review Manager software (RevMan V.5.3). Meta-analysis and\/or subgroup analysis will be performed on the included data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This study will investigate the application of GFW in the treatment or prevention of PCOS, and provide a high-quality synthesis to judge whether GFW is an effective and safe intervention for PCOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration number:<\/jats:title>\n            <jats:p>CRD42020192405<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022954","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T19:00:39Z","timestamp":1603911639000},"page":"e22954","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of different forms of Guizhi Fuling Wan on reproduction and metabolism in women with polycystic ovary syndrome"],"prefix":"10.1097","volume":"99","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine\/Reproductive & Women-Children Hospital of Chengdu University of Traditional Chinese, Chengdu City, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Hu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.18632\/oncotarget.23985","article-title":"Coronary artery disease risk in young women with polycystic ovary syndrome","volume":"9","author":"Ding","year":"2018","journal-title":"Oncotarget"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women\u201ds health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-sponsored 3rd PCOS consensus workshop group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.fertnstert.2017.12.023","article-title":"Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment","volume":"109","author":"Li","year":"2018","journal-title":"Fertil Steril"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.lfs.2019.04.046","article-title":"Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)","volume":"228","author":"Li","year":"2019","journal-title":"Life Sci"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/09513590.2013.871517","article-title":"Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS)","volume":"30","author":"Rutkowska","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","article-title":"Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials","volume":"35","author":"Facchinetti","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.psyneuen.2012.08.010","article-title":"Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression","volume":"38","author":"Kashani","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"R9-20230916","first-page":"31","article-title":"Discussion on classical prescriptions in the treatment of polycystic ovarian syndrome","volume":"52","author":"Yuan","year":"2018","journal-title":"Shanghai J Tradit Chin Med"},{"key":"R10-20230916","first-page":"803","article-title":"Clinical study of berberine combined with Guizhi Fuling Wan in patients with polycystic ovary syndrome with insulin resistance","volume":"26","author":"Shao","year":"2013","journal-title":"Chin J Clin Res"},{"key":"R11-20230916","first-page":"3211","article-title":"Effects of Guizhi Fuling Wan combined with metformin on insulin resistation-related inflammatory response and oxidative stress response in PCOS patients","volume":"23","author":"Cao","year":"2017","journal-title":"J Hainan Med Univ"},{"key":"R12-20230916","first-page":"832","article-title":"Based on network pharmacology and bioinformatics, analyze the mechanism of Guizhi Fuling Wan Bolus in the treatment of polycystic ovary syndrome","volume":"33","author":"Yu","year":"2019","journal-title":"Chin J Pharmacol Toxicol"},{"key":"R13-20230916","first-page":"116","article-title":"Effect of Guizhi Fuling Wan on insulin resistance and adiponectin in rats with polycystic ovary syndrome","volume":"44","author":"Zhao","year":"2012","journal-title":"J N Chin Med"},{"key":"R14-20230916","first-page":"320","article-title":"Effect of Guizhifu Ling Pill combined with berberine on patients with polycystic ovary syndrome with insulin resistance","volume":"19","author":"Tao","year":"2013","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"R15-20230916","first-page":"586","article-title":"Clinical research progress of Guizhi Fuling Wan in the treatment of infertility","volume":"37","author":"Wu","year":"2020","journal-title":"J Guangzhou Univ Tradit Chin Med"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"R20-20230916","article-title":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019)","author":"Higgins","year":"2019","journal-title":"Cochrane"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:55:47Z","timestamp":1694829347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022954"}},"subtitle":["A protocol for a meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":20,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022954","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}